NervGen Pharma (TSE:NGEN) has released an update.
NervGen Pharma has announced the strategic appointment of seasoned executive Neil Klompas to its Board of Directors, aiming to bolster the company’s expertise as it advances NVG-291, a promising treatment for nervous system damage, through clinical trials. Klompas brings extensive experience in the biotech sector, which is expected to be instrumental for NervGen’s growth and the ongoing Phase 1b/2a study of their lead drug candidate.
For further insights into TSE:NGEN stock, check out TipRanks’ Stock Analysis page.
